Institute for Quality and Efficiency in Health Care

Simoctocog alfa for haemophilia A: No suitable data

Simoctocog alfa (trade name Nuwiq) has been approved since July 2014 for people with type A haemophilia, an inherited disorder that impairs blood clotting. The German Institute for Quality and Efficiency in Health Care (IQWiG) ...

Feb 20, 2015
popularity not rated yet | comments 0

Lurasidone in schizophrenia: Added benefit is not proven

The drug lurasidone (trade name Latuda) has been available since November 2014 for the treatment of adults with schizophrenia. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment ...

Feb 06, 2015
popularity not rated yet | comments 0

Added benefit of idelalisib is not proven

Idelalisib (trade name Zydelig) has been available since September 2014 for patients with follicular lymphoma or chronic lymphocytic leukaemia (CLL). The German Institute for Quality and Efficiency in Health Care (IQWiG) ...

Jan 08, 2015
popularity not rated yet | comments 0

Daclatasvir for hepatitis C: Added benefit not proven

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care (IQWiG) ...

Dec 10, 2014
popularity not rated yet | comments 0